98 results about "Interstitial lung disease" patented technology

The present invention relates to the use of carbon monoxide (CO) as a biomarker and therapeutic agent of heart, lung, liver, spleen, brain, skin and kidney diseases and other conditions and disease states including, for example, asthma, emphysema, bronchitis, adult respiratory distress syndrome, sepsis, cystic fibrosis, pneumonia, interstitial lung diseases, idiopathic pulmonary diseases, other lung diseases including primary pulmonary hypertension, secondary pulmonary hypertension, cancers, including lung, larynx and throat cancer, arthritis, wound healing, Parkinson's disease, Alzheimer's disease, peripheral vascular disease and pulmonary vascular thrombotic diseases such as pulmonary embolism. CO may be used to provide anti-inflammatory relief in patients suffering from oxidative stress and other conditions especially including sepsis and septic shock. In addition, carbon monoxide may be used as a biomarker or therapeutic agent for reducing respiratory distress in lung transplant patients and to reduce or inhibit oxidative stress and inflammation in transplant patients.

The present invention comprises artificial tissue constructs that serve as in vitro models of mammalian lung tissue. The artificial tissue constructs of the present invention comprise functionally equivalent in vitro tissue scaffolds that enable immunophysiological function of the lung. The constructs can serve as novel platforms for the study of lung diseases (e.g., interstitial lung diseases, fibrosis, influenza, RSV) as well as smoke- and smoking-related diseases. The artificial tissue constructs of the present invention comprise the two components of alveolar tissue, epithelial and endothelial cell layers.

Disclosed herein are methods, constructs, kits, and the like, which can be used for detecting and/or differentiating interstitial lung disease. For example, idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP) can be detected and/or differentiated using at least one biomarker.

The present disclosure provides methods for diagnosis of interstitial lung diseases (ILDs). The present disclosure provides methods for differential diagnosis of idiopathic pulmonary fibrosis from other ILDs. Compositions and kits useful in carrying out a subject method are also provided.

The present invention relates to novel interferon gamma polypeptide variants having interferon gamma (IFNG) activity, methods for their preparation, pharmaceutical compositions comprising the polypeptide variants and their use in the treatment of diseases, in particular for the treatment of interstitial pulmonary diseases, such as idiopathic pulmonary fibrosis. These novel polypeptide variants all comprise the substitution S99T as compared to the amino acid sequence of huIFNG or fragments thereof. By performing this mutation the naturally occurring N-glycosylation site present at position 97 is significantly better utilized. Preferably, the variants comprise further modifications, e.g. in order to increase the AUC of such variants when administered subcutaneously.

Formulations of human amniotic fluid and methods of use thereof for treatment of lung disorders, and/or injuries have been developed. The formulations are suitable for topical delivery to the lung for treatment of lung disorders including chronic obstructive pulmonary disorders (COPD), asthma, emphysema, bronchiectasis, chronic bronchitis, interstitial lung disease, alpha-1 antitrypsin emphysema, as well as for treatment of acute lung injuries. Methods including administering specifically formulated, diluted sterile de-cellularized human amniotic fluids topically to the lungs, preferably as aerosol droplets, are described. In particular, the methods involving administration of the amniotic fluid formulation in the form of aerosol droplets with size between about 1.5 μm to about 5 μm, preferably from about 2.5 μm to about 3.5 μm, inclusive, using apparatus such as high-efficiency vibrating mesh nebulizers, are described. Formulations described can treat, or prevent one or more symptoms of a chronic lung disorder.

The invention provides a method for predicting and verifying the curative effect of glucocorticoid based on image omics, which comprises the following steps: S1, acquiring an original medical image ofa patient using glucocorticoid to treat connective tissue disease related interstitial pulmonary disease, and dividing the obtained original medical image into a training group and a verification group; s2, performing quantification processing on the original medical image to obtain image omics feature data; s3, establishing a prediction model of the image omics characteristics in the training group, and performing test verification in the verification group; and step S4, determining effective clinical characteristics and image omics characteristic tags adopting glucocorticoid, and performingverification in a verification group. According to the method, the curative effect of glucocorticoid is predicted and verified on the basis of imaging omics so as to identify patients sensitive to glucocorticoid treatment, and a specific reference basis is provided for doctors to diagnose and treat patients with connective tissue related interstitial pulmonary diseases, so that the patients are effectively treated, and the success rate of treatment is increased.

The present invention pertains to the monitoring and treatment of lung transplant recipients. In particular, the invention pertains to the use of biomarkers to predict or detect post-lung transplantation complications (e.g., organ rejection, acute organ rejection, organ injury, bronchiolitis obliterans, bronchiolitis obliterans syndrome, organizing pneumonia), fibroproliferative repair responses, interstitial lung diseases (e.g., idiopathic pulmonary fibrosis and other fibrotic lung diseases), and other immune-mediated lung diseases (e.g., graft versus host disease, scleroderma).

In one or more embodiments, the present invention provides a novel biomarker which provides a link between a distinct clinical phenotype and a biochemical effect of an autoantibody on an enzyme implicated in disease pathogenesis. In particular, the present invention provides an isolated or purified human autoantibody to PAD3 protein. Methods of diagnosis of subjects for rheumatoid arthritis (RA) using these antibodies as well as diagnosis of the severity of RA in the subject, and methods for monitoring treatment of a subject with RA are also provided. The biomarkers provided herein are also useful in the diagnosis of connective tissue-interstitial lung disease (CT-ILD) in patients having or suspected of having RA.

The invention provides a medicament for treating chronic and intractable lung diseases by acupoint application and summer treatment for winter disease. The medicament is prepared by mixing and grinding white mustard seed, yanhusuo, manchurian wildginger, apricot kernel, processed ephedra herb, common curculigo rhizome and Chinese magnoliavine fruit, and adding fresh ginger juice and honey into the mixture to prepare ointment. The medicament is applied to acupoints in dog days, has definite curative effect of treating winter diseases, has the functions of warming lung and reducing phlegm, nourishing lung and arresting cough, and reinforcing kidney and relieving asthma, and can calm the lung for upper body and reinforce the kidney for the lower body so as to play a role in simultaneously treating principal and subordinate symptoms. By means of the advantages of natural climate, the medicament can fully play the therapeutic effect so as to achieve the effect of getting twice result with half the effort. Clinical effect observation of 86 chronic bronchitis patients, 92 bronchialasthma patients and 102 anaphylacticrhinitis patients proves that the total effective rate of the medicament reaches 91.8 percent, 90.2 percent and 86.2 percent respectively.

A pharmaceutical composition for a treatment of an interstitial lung disease is provided. The pharmaceutical composition comprises an effective amount of an active component being one selected from a group consisting of a KMUP compound, a KMUP monoquaternary ammonium salt and a KMUP monoquaternary ammonium complex salt, wherein the KMUP monoquaternary ammonium complex salt is synthesized by the KMUP compound and a carboxylic acid derivative of one selected from a group consisting of a statin, a non-steroid anti-inflammatory (NSAIDs) and an anti-asthmatic drug.

The invention discloses a traditional Chinese medicine composition for treating interstitial lung disease. The traditional Chinese medicine composition comprises the following components according to a certain weight ratio: bamboo leaves, raw gypsum, American ginseng, radix ophiopogonis, lily, dried rehamnnia root, prepared rehmannia root, fritillary bulb, radix scrophulariae, angelica sinensis, radix paeoniae alba, platycodon grandiflorum, rhizoma pinelliae, asparagus cochinchinensis, Chinese yam, radix stemonae, radix glehniae, frost mulberry leaves, chrysanthemum, schisandra chinensis, colla corii asini, cortex lycii radicis, astragalus membranaceus, rhizoma cimicifugae and radix bupleuri. The traditional Chinese medicine composition has the functions of clearing heat and promoting fluid production, boosting qi and nourishing yin, moistening lung and calming the nerves, replenishing and nourishing blood, and can be used for effectively treating interstitial lung disease.

The present invention provides methods for treating interstitial lung diseases, comprising administering to an individual an effective amount of an inhibitor of coagulation factor XII. The invention further provides uses and pharmaceutical kits for that treatment.

The present invention relates to a rhizoma polygoni cuspidati and rhizoma curcumae longae formula, and an application thereof in preparing a drug for treating interstitial lung disease, and also relates to a composition of the rhizoma polygoni cuspidati and rhizoma curcumae longae, and an application thereof in preparing a drug for treating the interstitial lung disease.

There is a method of treating or preventing interstitial lung disease in a patient. The method includes the step of administering to the patient a therapeutically effective amount of the compound of the following formula:

or a pharmaceutically acceptable salt thereof.